3 Hyped Up Stocks We Steer Clear Of

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. All that said, here are three overhyped stocks that may correct and some you should consider instead.

SiteOne (SITE)

One-Month Return: +6.4%

Known for distributing John Deere tractors and LESCO turf care products, SiteOne Landscape Supply (NYSE:SITE) provides landscaping products and services to professionals, including irrigation, lighting, and nursery supplies.

Why Are We Out on SITE?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Earnings per share fell by 3.9% annually over the last two years while its revenue grew, showing its incremental sales were much less profitable
3. Waning returns on capital imply its previous profit engines are losing steam

SiteOne is trading at $156.97 per share, or 35.2x forward P/E. Read our free research report to see why you should think twice about including SITE in your portfolio.

Textron (TXT)

One-Month Return: +4.5%

Listed on the NYSE in 1947, Textron (NYSE:TXT) provides products and services in the aerospace, defense, industrial, and finance sectors.

Why Is TXT Not Exciting?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 4% for the last two years
2. Earnings growth underperformed the sector average over the last two years as its EPS grew by just 4.5% annually
3. 3.4 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

Textron’s stock price of $98.47 implies a valuation ratio of 15.3x forward P/E. Dive into our free research report to see why there are better opportunities than TXT.

Gilead Sciences (GILD)

One-Month Return: +24.4%

From its groundbreaking work in developing the first single-tablet regimens for HIV treatment, Gilead Sciences (NASDAQ:GILD) develops and markets innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, and cancer.

Why Does GILD Give Us Pause?

1. The company has faced growth challenges as its 3.6% annual revenue increases over the last five years fell short of other healthcare companies
2. 7.5 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. Eroding returns on capital suggest its historical profit centers are aging

At $155.39 per share, Gilead Sciences trades at 17.4x forward P/E. To fully understand why you should be careful with GILD, check out our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.